Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김범산 | * |
dc.date.accessioned | 2018-12-14T16:31:07Z | - |
dc.date.available | 2018-12-14T16:31:07Z | - |
dc.date.issued | 2018 | * |
dc.identifier.issn | 0969-8051 | * |
dc.identifier.other | OAK-22485 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/247814 | - |
dc.description.abstract | Introduction: Global and regional sympathetic activity in the heart can be evaluated using [123I]meta-iodobenzylguanidine ([123I]mIBG) imaging. However, [123I]mIBG is associated with low image spatial resolution and sensitivity in cardiac imaging. We investigated the capability of an F-18-labeled mIBG derivative, meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG), for identifying ischemic and viable myocardium in a rat model of myocardial infarction. Materials and methods: The ex vivo biodistribution and in vivo metabolic stability of [18F]mFPBG were investigated in Sprague–Dawley rats. Selective cardiac adrenergic activation was confirmed via a blocking experiment involving pretreatment with desipramine (2 mg kg−1), followed by the administration of [18F]mFPBG. Imaging properties of [18F]mFPBG were compared with those of traditional cardiac imaging radiotracers ([123I]mIBG and [99mTc]MIBI) in a rat model of myocardial infarction. Non-invasive image-based measurements of infarct sizes were then compared with histological findings by using Bland–Altman analysis. Results: The differences in infarct sizes determined using histological analysis and [18F]mFPBG PET were −2.55 ± 4.99% (range: −12.33 to 7.22), −2.35 ± 3.32% (range: −8.87 to 4.16), and −3.15 ± 6.16% (range: −15.24 to 8.93) at 5, 20, and 40 min, respectively. Furthermore, [18F]mFPBG PET was superior to traditional imaging methods in assessing the degree of ischemia in areas of myocardial infarction, as well as the actual infarct size. Conclusion: Compared to [123I]mIBG, [18F]mFPBG showed improved spatial resolution and sensitivity in a rat model of myocardial infarction. This result suggested that [18F]mFPBG is a promising cardiac PET imaging agent for potential diagnostic application in PET cardiology. © 2018 Elsevier Inc. | * |
dc.description.sponsorship | Ministry of Science, ICT and Future Planning | * |
dc.language | English | * |
dc.publisher | Elsevier Inc. | * |
dc.subject | 18F | * |
dc.subject | Cardiac sympathetic innervation | * |
dc.subject | Guanidine | * |
dc.subject | Myocardial infarction | * |
dc.subject | PET | * |
dc.title | Feasibility of myocardial PET imaging using a benzylguanidine analog: meta-(3-[18F]fluoropropyl)benzylguanidine ([18F]mFPBG) | * |
dc.type | Article | * |
dc.relation.volume | 61 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 63 | * |
dc.relation.lastpage | 70 | * |
dc.relation.journaltitle | Nuclear Medicine and Biology | * |
dc.identifier.doi | 10.1016/j.nucmedbio.2018.04.005 | * |
dc.identifier.wosid | WOS:000437551700008 | * |
dc.identifier.scopusid | 2-s2.0-85047090343 | * |
dc.author.google | Woo S.-K. | * |
dc.author.google | Moon B.S. | * |
dc.author.google | Kim B.S. | * |
dc.author.google | Kim M.H. | * |
dc.author.google | Lee Y.J. | * |
dc.author.google | Jung J.H. | * |
dc.author.google | Lee K.C. | * |
dc.author.google | Seo Y. | * |
dc.author.google | Kim W. | * |
dc.author.google | Lim S.M. | * |
dc.author.google | Lee B.C. | * |
dc.author.google | Kim S.E. | * |
dc.contributor.scopusid | 김범산(35223582600) | * |
dc.date.modifydate | 20240123125716 | * |